Clinical Trials Logo

Tardive Dyskinesia clinical trials

View clinical trials related to Tardive Dyskinesia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02252380 Active, not recruiting - Parkinson's Disease Clinical Trials

ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

Start date: May 2015
Phase: N/A
Study type: Interventional

The proposed study is to evaluate the effectiveness of ExAblate Transcranial MRgFUS as a tool for creating a unilateral lesion in the Vim thalamus or the globus pallidus (GPi) in patients with treatment-refractory symptoms of movement disorders.

NCT ID: NCT01804920 Active, not recruiting - Tardive Dyskinesia Clinical Trials

D-Serine Treatment For Tardive Dyskinesia

Start date: January 2013
Phase: N/A
Study type: Interventional

Presently no generally effective treatments for tardive dyskinesia (TD) are available. D-serine is a naturally occurring amino acid that acts in-vivo as positive allosteric modulator at the glycine site associated with the glutamatergic NMDA receptor. Previous studies have suggested that D-serine may improve motor symptoms, including dyskinesias, which are caused by treatment with presently used antipsychotics drugs. The hypothesis under investigation in the present study is that D-serine adjuvant treatment may improve TD in schizophrenia patients diagnosed with this disorder.